Revenue + Forward P/E
Halozyme Therapeutics, Inc. (HALO) quarterly revenue and forward P/EForward P/E: 11.0x
RevenueRevenue (est)Forward P/E
Fair value & valuation models
Fair value models are a Plus feature
Upgrade to Plus for the interactive DCF model, valuation bands, and implied-price scenarios.
71% OFF$23.99 $6.99/mo
Ends in23:59:59
Cancel anytime. Secure checkout via Stripe.
Valuation
Market cap
$11.87B
Enterprise value
$11.42B
P/E ratio (TTM)
27.68x
P/S ratio (TTM)
6.36x
P/B ratio
43.48x
EV/Sales
7.57x
EV/EBITDA
18.31x
Dividend yield
0.00%
Income statement (TTM)
Revenue (TTM)
$1.40B
Gross profit (TTM)
$1.09B
Operating income (TTM)
$816.29M
EBITDA (TTM)
$573.05M
Net income (TTM)
$316.89M
Free cash flow (TTM)
$644.59M
Margins & returns
Gross margin
76.93%
Operating margin
56.96%
Profit margin
23.13%
Return on equity
126.27%
Return on assets
13.05%
Per-share metrics
EPS (TTM)
$2.95
Dividend yield
0.00%
Beta
0.84
Capital structure
Cash & equivalents
$133.82M
Total debt
$2.14B
Net debt
$2.01B
Shares outstanding
118.61M
Financial health
Current ratio
4.66
Debt / equity
43.89
Debt / assets
0.85
Interest coverage
45.03
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.15T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $629.85B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $443.16B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $365.38B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $354.73B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $332.46B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $11.87B | 27.68x | 6.36x | 18.31x | - |